@article{oai:nagasaki-u.repo.nii.ac.jp:00005457,
 author = {Kumagami, Takeshi and Wakiyama, Harumi and Kusano, Mao and Kajiyama, Ayano and Miura, Yoko and Uematsu, Masafumi and Yoneda, Ai and Kurihara, Junko and Suzuma, Kiyoshi and Kitaoka, Takashi},
 issue = {4},
 journal = {Journal of Ocular Pharmacology and Therapeutics},
 month = {May},
 note = {Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (TaprosR: tafluprost) has been reduced to balance corneal safety and preservative effectiveness (old formulation: 0.01%; new formulation: 0.001%). However, no reports have been published on its clinical effect. Therefore, we conducted a clinical research study to compare the safety of BAK-reduced tafluprost on the ocular surface with other prostaglandin ophthalmic solutions. Methods: This clinical study included 28 glaucoma patients (28 eyes) with a treatment history of latanoprost ophthalmic solution (XalatanR) or travoprost ophthalmic solution (Travatan Z R), who presented with corneal epithelial disorders. The subjects were switched to BAK-reduced tafluprost, and its effect on the ocular surface was examined after 1 and 2 months of treatment [using fluorescein staining score, hyperemia, tear film breakup time, and intraocular pressure (IOP) lowering]. Results: In all analyzed subjects (N=27), the fluorescein staining score was significantly improved after switching to BAK-reduced tafluprost (P<0.0001). Conversely, the IOP-lowering effect was not notably changed. The subjects switched from latanoprost (n=10) showed significant improvement in fluorescein staining score (P<0.05) as well as in IOP lowering (P<0.01). The subjects switched from travoprost (n=17) also showed significant improvement in fluorescein staining score (P<0.001), but without a significant change in IOP lowering. Conclusions: Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect, but also for its good corneal safety profile., Journal of Ocular Pharmacology and Therapeutics, 30(4), pp.340-345; 2014},
 pages = {340--345},
 title = {Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions},
 volume = {30},
 year = {2014}
}